17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Swiss pharma giant Roche today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20–24 September 2021. 24 September 2021
Otsuka Pharmaceutical company Astex Pharmaceuticals has provided new Phase III data from the ASCERTAIN trial of Inqovi (decitabine/cedazuridine). 24 September 2021
R-Pharm, one of Russia’s leading drugmakers, has started the production of a vaccine against COVID-19 under a license from Oxford University and UK pharma major AstraZeneca, according to recent statements made by some Russian state officials and local media reports. 24 September 2021
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and how they impact its future. 24 September 2021
The World Health Organization's Director General Tedros Adhanom Ghebreyesus has thanked India's Minister Mansukh Mandaviya for announcing that India will resume crucial COVID-19 vaccine shipments to COVAX in October. 23 September 2021
Research undertaken at the University of Bristol, UK, paves the way for a novel artificial intelligence (AI)-driven platform for growing and treating virtual tumors. 22 September 2021
Research from industry analyst GlobalData finds an increasing rate of dealmaking in India in recent quarters, propelled by the coronavirus pandemic. 21 September 2021
Uwe Trinks, global practice lead for pharmacovigilance technologies, IQVIA, provides an Expert View on how the pharmaceutical industry can make a success of new working practices. 21 September 2021
In a world reeling from the coronavirus pandemic, the pharmaceutical industry has been leading the global response, not only for its enormous contribution to the management of COVID-19, but also for its tireless commitment to continue developing therapies for different diseases that afflict populations. 21 September 2021
Anglo-Swedish pharma major AstraZeneca today revealed plans to establish a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland, to ensure the company’s global supply network is fit for future growth. 21 September 2021
At the annual congress of the European Society of Medical Oncology (ESMO), Swiss drugmaker Novartis has announced important new data for its CDK4/6 inhibitor Kisqali (ribociclib). 20 September 2021
At the annual congress of the European Society of Medical Oncology (ESMO 2021), Japan’s Astellas Pharma and partner Pfizer are offering new data for Xtandi (enzalutamide). 17 September 2021
Spanish plasma specialist Grifols today proposed a 1.6 billion-euro ($1.9 billion) takeover of its German rival Biotest, in a move to consolidate the plasma-based drug industry. , 17 September 2021
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit of AbbVie and Roche’s Venclexta/Venclexto (venetoclax) in combination with a hypomethylating agent (HMA) offers an added benefit over the appropriate comparator therapy for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. 17 September 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.